INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to plan for future clinical trials in patients with metastatic
urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT
fluoroscopy guidance into bone, lymph node, soft tissue and liver metastases in subjects with
metastatic prostate cancer, urothelial carcinoma, or renal cell carcinoma. Pre- and
post-injection CT images will be obtained to determine the injection parameters needed for
optimal distribution throughout metastases of a given size. A biopsy of the metastatic site
will also be obtained to validate expression of the receptor CD155.